Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation

Condition(s) studied

Investigational drug(s) / intervention(s)

terlipressin: Patients randomized to the intervention group received terlipressin during renal artery anastomosis to achieve a target mean arterial pressure (MAP) of at least 100 mmHg before graft reperfusion. Terlipressin was prepared as 1 mg diluted to 10 mL and administered via syringe pump at 60 mL/h (approximately 10 minutes for full administration). Administration was initiated when MAP was below the target level (\<100 mmHg) before graft reperfusion and could be discontinued when MAP was considered adequately above the target level according to the investigator's clinical judgment.

Placebo (Normal Saline): Participants assigned to the control group received an equivalent volume of normal saline administered via syringe pump during renal artery anastomosis using the same procedure and infusion rate as the intervention group to maintain blinding.

Study summary

Prospective double blind randomized controlled trial. By randomizing patients undergoing kidney transplantation into a conventional catecholamine drug (dobutamine) blood pressure maintenance group and a terlipressin-complexed dobutamine group, the investigators compared the effect of intraoperative blood pressure maintenance and the dosage of the vasoactive drug, postoperative graft function, delayed graft function, and other related complications between the two groups, in order to demonstrate whether the use of terlipressin for blood pressure regulation during kidney transplantation is superior to the existing treatments.

Eligibility

Primary outcome measure(s)

• Delayed graft function (DGF) — Within 7 days after kidney transplantation
  Delayed graft function (DGF) was defined as the need for any dialysis treatment within the first 7 days after kidney transplantation.

Trial sites (1)

More Beijing Friendship Hospital trials in China

Other trials for the same condition